Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;6(2):43-48.
doi: 10.15171/jnp.2017.07. Epub 2016 Oct 27.

Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review

Tito Zattera  1 , Francesco Londrino  2 , Matteo Trezzi  1 , Roberto Palumbo  2 , Antonio Granata  3 , Paola Tatangelo  2 , Valentina Corbani  1 , Valeria Falqui  1 , Nadia Chiappini  1 , Lisa Mathiasen  4 , Marco Cavallini  5 , Davide Rolla  1
Affiliations

Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review

Tito Zattera et al. J Nephropathol. 2017 Mar.

Abstract

Background: Pemetrexed (PEM) is a new-generation multitargeted antifolate agent with a demonstrated broad-spectrum activity in several types of human cancers, including non-small cell lung cancer (NSCLC) and mesothelioma. Major side effects include dose-limiting hematologic toxicities. PEM nephrotoxicity is well known; however, its frequency is considered to be low.

Case presentation: Here we report two cases of acute kidney injury (AKI) related to PEM administration (500 mg/m2) in patients with NSCLC. The first patient required hemodialysis treatment and was submitted to renal biopsy which showed acute tubular damage and interstitial edema without acute tubular necrosis. No other potential nephrotoxic agents were identified. The second patient developed AKI, not proven by biopsy and did not require renal replacement therapy. Both patients, on regular supplementation with folic acid and vitamin B12, concomitantly developed myelosuppression and even several months after PEM withdrawal, showed only a modest improvement of renal function.

Conclusions: PEM is an antifolate antineoplastic agent with a broad-spectrum activity in locally advanced or metastatic NSCLC. It has been shown that PEM allows longer survival. The risk of acute or chronic kidney disease may be one of the prices to be paid for this success.

Keywords: Acute kidney injury; Nephrotoxicity; Pemetrexed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
See this image and copyright information in PMC

References

    1. Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012;15(4):183–210. doi: 10.1016/j.drup.2012.07.002. - DOI - PubMed
    1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44. doi: 10.1200/JCO.2003.11.136. - DOI - PubMed
    1. Santoro A, O’Brien ME, Stahe RA, Nackaerts K, Baas P, Karthaus M. et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol. 2008;3(7):756–63. doi: 10.1097/JTO.0b013e31817c73d6. - DOI - PubMed
    1. Schuette WH, Groschel A, Sebastian M, Andreas S, Muller T, Schneller T. et al. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer. 2013;14(3):215–23. doi: 10.1016/j.cllc.2012.10.001. - DOI - PubMed
    1. Socinski MA, Stinchcombe TE, Hayes DN. The evolving role of pemetrexed (Alimta) in lung cancer. Semin Oncol. 2005;32(2 Suppl 2):16–22. - PubMed

LinkOut - more resources